Health Care [ 3/12 ] | Biotechnology [ 26/73 ]
NASDAQ | Common Stock
Lexaria Bioscience Corp. operates as a biotechnology company.
It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids.
Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.
The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016.
Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 18, 25 | -0.21 Decreased by -61.54% | -0.16 Decreased by -34.01% |
| Apr 7, 25 | -0.15 Decreased by -150.00% | -0.16 Increased by +8.14% |
| Jan 10, 25 | -0.16 Decreased by -23.08% | -0.12 Decreased by -33.33% |
| Nov 19, 24 | -0.15 Decreased by -25.00% | -0.11 Decreased by -36.36% |
| Jul 12, 24 | -0.13 Increased by +64.86% | -0.10 Decreased by -30.00% |
| Apr 9, 24 | -0.06 Increased by +72.49% | -0.10 Increased by +40.00% |
| Jan 12, 24 | -0.13 Increased by +56.67% | -0.11 Decreased by -18.18% |
| Nov 20, 23 | -0.12 Increased by +50.00% | -0.13 Increased by +7.69% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| May 31, 25 | 174.00 K Increased by +107.14% | -3.79 M Decreased by -112.67% | Decreased by -2.18 K% Decreased by -2.67% |
| Feb 28, 25 | 174.00 K Increased by +20.00% | -2.71 M Decreased by -317.71% | Decreased by -1.56 K% Decreased by -248.09% |
| Nov 30, 24 | 183.92 K Increased by +21.58% | -2.70 M Decreased by -129.26% | Decreased by -1.47 K% Decreased by -88.57% |
| Aug 31, 24 | 84.00 K Increased by +2.55 K% | -2.18 M Decreased by -76.29% | Decreased by -2.60 K% Decreased by -107.20% |
| May 31, 24 | 84.00 K Decreased by -9.82% | -1.78 M Increased by +24.87% | Decreased by -2.12 K% Increased by +16.69% |
| Feb 29, 24 | 145.00 K Increased by +624.09% | -649.54 K Increased by +49.96% | Decreased by -447.96% Increased by +93.09% |
| Nov 30, 23 | 151.28 K Increased by +49.08% | -1.18 M Increased by +32.84% | Decreased by -779.57% Increased by +54.95% |
| Aug 31, 23 | -3.43 K Decreased by -103.09% | -1.24 M Increased by +15.55% | Increased by +36.10 K% Increased by +2.83 K% |